Literature DB >> 25787030

Engineering solid lipid nanoparticles for improved drug delivery: promises and challenges of translational research.

Dinesh Kumar Mishra1, Vinod Dhote, Punit Bhatnagar, Pradyumna Kumar Mishra.   

Abstract

Nanotechnology is expected to revolutionize existing drug delivery. Many nanostructured systems have been employed for drug delivery and yielded some promising results. Solid lipid nanoparticles (SLN) have been looked at as a potential drug carrier system since last two decades. SLN do not show biotoxicity as they are prepared from physiological lipids. SLN are especially useful in drug delivery as they can enhance the absorption of drugs and improves the bioavailability of both hydrophilic and lipophilic drugs. This paper presents an overview about the various classes of SLN, comparison with available drug carrier systems, different ways of production, in vivo fate and biodistribution and various applications of SLN. Besides, aspects of stability, hurdles and strategies for SLN manufacturing with potential of clinical translation are also discussed.

Entities:  

Year:  2012        PMID: 25787030     DOI: 10.1007/s13346-012-0088-9

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  56 in total

Review 1.  Solid lipid nanoparticles: production, characterization and applications.

Authors:  W Mehnert; K Mäder
Journal:  Adv Drug Deliv Rev       Date:  2001-04-25       Impact factor: 15.470

Review 2.  Stabilization of proteins in dry powder formulations using supercritical fluid technology.

Authors:  Natasa Jovanović; Andréanne Bouchard; Gerard W Hofland; Geert-Jan Witkamp; Daan J A Crommelin; Wim Jiskoot
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

Review 3.  Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems.

Authors:  M Uner
Journal:  Pharmazie       Date:  2006-05       Impact factor: 1.267

Review 4.  Solid lipid nanoparticles as a drug delivery system for peptides and proteins.

Authors:  António J Almeida; Eliana Souto
Journal:  Adv Drug Deliv Rev       Date:  2007-05-01       Impact factor: 15.470

Review 5.  Non-viral nucleic acid delivery: key challenges and future directions.

Authors:  Mahmoud Elsabahy; Adil Nazarali; Marianna Foldvari
Journal:  Curr Drug Deliv       Date:  2011-05       Impact factor: 2.565

6.  The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle.

Authors:  Zhinan Mei; Xiaokuan Li; Qunrong Wu; Sheng Hu; Xiangliang Yang
Journal:  Pharmacol Res       Date:  2005-04       Impact factor: 7.658

7.  Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model.

Authors:  Loredana Serpe; Roberto Canaparo; Marco Daperno; Raffaello Sostegni; Germana Martinasso; Elisabetta Muntoni; Laura Ippolito; Nicoletta Vivenza; Angelo Pera; Mario Eandi; Maria Rosa Gasco; Gian Paolo Zara
Journal:  Eur J Pharm Sci       Date:  2010-02-04       Impact factor: 4.384

8.  Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin.

Authors:  Robhash Kusam Subedi; Keon Wook Kang; Hoo-Kyun Choi
Journal:  Eur J Pharm Sci       Date:  2009-05-03       Impact factor: 4.384

9.  Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery.

Authors:  Qingzhi Lv; Aihua Yu; Yanwei Xi; Houli Li; Zhimei Song; Jing Cui; Fengliang Cao; Guangxi Zhai
Journal:  Int J Pharm       Date:  2009-01-22       Impact factor: 5.875

10.  Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance.

Authors:  Ayman Khdair; Di Chen; Yogesh Patil; Linan Ma; Q Ping Dou; Malathy P V Shekhar; Jayanth Panyam
Journal:  J Control Release       Date:  2009-09-11       Impact factor: 9.776

View more
  12 in total

1.  In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions-a metabolic approach.

Authors:  Luciana Damacena Silva; Nayana Ferreira Lima; Eva Carolina Arrua; Claudio Javier Salomon; Marina Clare Vinaud
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

2.  Extended-release Buprenorphine, an FDAindexed Analgesic, Attenuates Mechanical Hypersensitivity in Rats (Rattus norvegicus).

Authors:  Eden D Alamaw; Benjamin D Franco; Katechan Jampachaisri; Monika K Huss; Cholawat Pacharinsak
Journal:  J Am Assoc Lab Anim Sci       Date:  2021-12-16       Impact factor: 1.706

3.  Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice.

Authors:  L DeTolla; R Sanchez; E Khan; B Tyler; M Guarnieri
Journal:  J Vet Med       Date:  2014-11-27

4.  Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs.

Authors:  Michael Guarnieri; Betty M Tyler; Louis Detolla; Ming Zhao; Barry Kobrin
Journal:  J Pharm Bioallied Sci       Date:  2014-01

5.  Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats.

Authors:  M Guarnieri; C Brayton; R Sarabia-Estrada; B Tyler; P McKnight; L DeTolla
Journal:  J Vet Med       Date:  2017-04-09

6.  Development of solid lipid nanoparticles containing total flavonoid extract from Dracocephalum moldavica L. and their therapeutic effect against myocardial ischemia-reperfusion injury in rats.

Authors:  Mei-E Tan; Cheng-Hui He; Wen Jiang; Cheng Zeng; Ning Yu; Wei Huang; Zhong-Gao Gao; Jian-Guo Xing
Journal:  Int J Nanomedicine       Date:  2017-04-19

7.  A Long-Term Study of a Lipid-Buprenorphine Implant in Rats.

Authors:  Michael Guarnieri; Cory Brayton; Betty M Tyler
Journal:  J Vet Med       Date:  2018-07-09

8.  Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats.

Authors:  Alan Cowan; Rachel Sarabia-Estrada; Gina Wilkerson; Patrick McKnight; Michael Guarnieri
Journal:  Lab Anim (NY)       Date:  2016-01       Impact factor: 12.625

9.  Lipid bound extended release buprenorphine (high and low doses) and sustained release buprenorphine effectively attenuate post-operative hypersensitivity in an incisional pain model in mice (Mus musculus).

Authors:  Kaela Navarro; Katechan Jampachaisri; Monika Huss; Cholawat Pacharinsak
Journal:  Animal Model Exp Med       Date:  2021-03-23

Review 10.  Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives.

Authors:  Zehra Edis; Junli Wang; Muhammad Khurram Waqas; Muhammad Ijaz; Munazza Ijaz
Journal:  Int J Nanomedicine       Date:  2021-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.